269 related articles for article (PubMed ID: 27013611)
1. Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII.
O'Sullivan JM; Jenkins PV; Rawley O; Gegenbauer K; Chion A; Lavin M; Byrne B; O'Kennedy R; Preston RJ; Brophy TM; O'Donnell JS
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):855-63. PubMed ID: 27013611
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII.
Kannicht C; Ramström M; Kohla G; Tiemeyer M; Casademunt E; Walter O; Sandberg H
Thromb Res; 2013 Jan; 131(1):78-88. PubMed ID: 23058466
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
Mannully ST; L N R; Pulicherla KK
Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.
Stowell SR; Arthur CM; Mehta P; Slanina KA; Blixt O; Leffler H; Smith DF; Cummings RD
J Biol Chem; 2008 Apr; 283(15):10109-23. PubMed ID: 18216021
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of a codon-optimized blood coagulation factor VIII.
Shestopal SA; Hao JJ; Karnaukhova E; Liang Y; Ovanesov MV; Lin M; Kurasawa JH; Lee TK; Mcvey JH; Sarafanov AG
J Thromb Haemost; 2017 Apr; 15(4):709-720. PubMed ID: 28109042
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction.
Kolind MP; Nørby PL; Berchtold MW; Johnsen LB
J Biotechnol; 2011 Feb; 151(4):357-62. PubMed ID: 21219947
[TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen.
Bian CF; Zhang Y; Sun H; Li DF; Wang DC
PLoS One; 2011; 6(9):e25007. PubMed ID: 21949831
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
[TBL] [Abstract][Full Text] [Related]
12. Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products.
Chun H; Pettersson JR; Shestopal SA; Wu WW; Marakasova ES; Olivares P; Surov SS; Ovanesov MV; Shen RF; Sarafanov AG
J Thromb Haemost; 2021 Apr; 19(4):954-966. PubMed ID: 33527662
[TBL] [Abstract][Full Text] [Related]
13. Production of Recombinant Factor VIII in Human Cell Lines.
Fantacini DMC; Picanço-Castro V
Methods Mol Biol; 2018; 1674():63-74. PubMed ID: 28921428
[TBL] [Abstract][Full Text] [Related]
14. Proteome-wide Identification of Glycosylation-dependent Interactors of Galectin-1 and Galectin-3 on Mesenchymal Retinal Pigment Epithelial (RPE) Cells.
Obermann J; Priglinger CS; Merl-Pham J; Geerlof A; Priglinger S; Götz M; Hauck SM
Mol Cell Proteomics; 2017 Aug; 16(8):1528-1546. PubMed ID: 28576849
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.
Mikkelsen J; Thomsen J; Ezban M
Biochemistry; 1991 Feb; 30(6):1533-7. PubMed ID: 1899619
[TBL] [Abstract][Full Text] [Related]
16. Structural study of the sugar chains of porcine factor VIII--tissue- and species-specific glycosylation of factor VIII.
Hironaka T; Furukawa K; Esmon PC; Yokota T; Brown JE; Sawada S; Fournel MA; Kato M; Minaga T; Kobata A
Arch Biochem Biophys; 1993 Dec; 307(2):316-30. PubMed ID: 8274017
[TBL] [Abstract][Full Text] [Related]
17. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
Canis K; Anzengruber J; Garenaux E; Feichtinger M; Benamara K; Scheiflinger F; Savoy LA; Reipert BM; Malisauskas M
J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888865
[TBL] [Abstract][Full Text] [Related]
18. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
[TBL] [Abstract][Full Text] [Related]
19. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
20. Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies.
Ito J; Baldwin WH; Cox C; Healey JF; Parker ET; Legan ER; Li R; Gill S; Batsuli G
J Thromb Haemost; 2022 Mar; 20(3):574-588. PubMed ID: 34863021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
